Summary & Overview
CPT 90621: Meningococcal Recombinant Lipoprotein Vaccine, IM
CPT code 90621 represents the intramuscular administration of a meningococcal recombinant lipoprotein vaccine given as part of a two- or three-dose schedule to prevent meningococcal disease in individuals aged 10 years and older at risk. This immunization code is nationally relevant because meningococcal disease prevention is a public health priority and vaccination coding affects coverage, reporting, and vaccine delivery workflows across outpatient settings. Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise explanation of what CPT code 90621 covers, the clinical context for its use, and the typical sites where the service is delivered. The publication summarizes payer coverage patterns and common administrative modifiers used with vaccine administration claims. It also provides benchmarks on utilization and notes recent policy or coding clarifications that affect billing and reimbursement for meningococcal immunization services. The content is intended to help billing staff, clinicians, and policy analysts understand the code’s purpose, operational considerations, and the payer landscape at a national level.
Billing Code Overview
CPT code 90621 describes administration of a meningococcal recombinant lipoprotein vaccine given intramuscularly as part of a two- or three-dose schedule to prevent meningococcal disease (for example, infections caused by Neisseria meningitidis). The service is indicated for individuals 10 years and older who are at risk for meningococcal disease.
Service type: Vaccine administration (intramuscular), preventative immunization
Typical site of service: Outpatient clinic, physician office, public health clinic, or other ambulatory care settings where routine vaccinations are provided.
Clinical & Coding Specifications
Clinical Context
A 17-year-old adolescent presents to a primary care clinic for routine immunizations prior to high school entry and participation in boarding activities. The clinical workflow includes confirmation of prior meningococcal vaccine doses and immunization history, verification of indication for meningococcal recombinant lipoprotein vaccine, informed consent, screening for contraindications (severe allergy to vaccine components), preparation of the intramuscular vaccine, and administration of a single dose as part of a two- or three-dose schedule. Observation for immediate adverse reactions for 15 minutes follows administration. Documentation in the medical record includes the vaccine lot number, manufacturer, route, site, and the use of 90621 for billing. Typical sites of service are outpatient clinic, pediatric office, community health center, or college health service. The typical patient is age 10 years or older and at increased risk for meningococcal disease due to travel, outbreak exposure, or specific medical conditions requiring enhanced protection.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when an E/M visit is performed and documented separately from vaccine administration on the same day. |